ME23andMe Holding Co.

Nasdaq 23andme.com


$ 0.41 $ 0.00 (-0.87 %)    

Wednesday, 12-Jun-2024 15:59:30 EDT
QQQ $ 476.76 $ 6.13 (1.31 %)
DIA $ 387.57 $ -0.28 (-0.07 %)
SPY $ 541.15 $ 4.41 (0.82 %)
TLT $ 92.53 $ 0.69 (0.75 %)
GLD $ 214.71 $ 0.57 (0.27 %)
$ 0.4121
$ 0.42
$ 0.00 x 0
$ 0.00 x 0
$ 0.41 - $ 0.42
$ 0.35 - $ 2.03
2,558,391
na
196.87M
$ 1.82
nm
TBD
na
na ($ 0.00)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
1 05-30-2024 03-31-2024 10-K
2 02-07-2024 12-31-2023 10-Q
3 11-08-2023 09-30-2023 10-Q
4 08-08-2023 06-30-2023 10-Q
5 05-25-2023 03-31-2023 10-K
6 02-08-2023 12-31-2022 10-Q
7 11-07-2022 09-30-2022 10-Q
8 08-09-2022 06-30-2022 10-Q
9 05-27-2022 03-31-2022 10-K
10 02-11-2022 12-31-2021 10-Q
11 11-10-2021 09-30-2021 10-Q
12 08-13-2021 06-30-2021 10-Q
13 06-03-2021 03-31-2021 10-Q
14 03-24-2021 12-31-2020 10-K
15 11-16-2020 09-30-2020 10-Q
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

Core News & Articles

- Reuters

 23andme-therapeutics-present-preliminary-phase-2-safety-and-efficacy-results-for-23me-00610-targeting-cd200r1-at-the-2024-asco-annual-meeting

– 23ME-00610 monotherapy demonstrates preliminary evidence of clinical benefit, including one confirmed partial response – 23ME...

 23andme-holding-q4-2024-gaap-eps-043-sales-64028m-beat-55822m-estimate

23andMe Holding (NASDAQ:ME) reported quarterly losses of $(0.43) per share. The company reported quarterly sales of $64.028 mi...

Core News & Articles

Lemonaid Health will offer customers more affordable access to branded ED medication STENDRA that may be taken as early as ~15 ...

 23andme-holding-granted-additional-180-days-or-until-nov-4-to-regain-compliance-with-minimum-bid-price-requirement-for-continued-listing

-SEC Filing

 23andme-to-present-preliminary-efficacy-and-biomarker-data-for-23me-00610-at-the-2024-asco-annual-meeting

23andMe Holding Co. (NASDAQ:ME) ("23andMe"), a leading human genetics and biopharmaceutical company, today announced th...

 once-valued-at-billions-23andmes-ceo-considers-privatization-to-secure-companys-future

Anne Wojcicki, CEO of 23andMe mulls taking the genetics company private amid market challenges. With declining revenue and a fo...

 23andme-reveals-ceos-intention-to-pursue-potential-take-private

Wojcicki currently owns shares constituting more than 20% of the total outstanding shares and entitling her to approximately 49...

 citigroup-maintains-neutral-on-23andme-holding-lowers-price-target-to-047

Citigroup analyst Daniel Grosslight maintains 23andMe Holding (NASDAQ:ME) with a Neutral and lowers the price target from $0...

 23andme-to-present-data-on-two-clinical-stage-immuno-oncology-programs-at-the-aacr-annual-meeting-2024

23ME-01473, antibody targeting ULBP6: Data will be presented on the discovery and biology of ULBP6, and the potential to restor...